Although usually benign, anterior pituitary tumours occasionally exhibit aggressive
behaviour, with invasion of surrounding tissues, rapid growth, resistance to conventional …

Neuroendocrine tumours (NET) of the gastrointestinal tract and the lung are a rare and
heterogeneous group of tumours. The molecular characterization and the clinical …

Tumor cells overexpress surface markers which are absent from normal cells. These tumor-
restricted antigenic signatures are a fundamental basis for distinguishing on-target from off …

Peptide receptor radionuclide therapy (PRRT) is an important treatment option for patients
with somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though …

Both somatostatin (SST) and somatostatin receptors (SSTRs) are proteins with important
functions in both physiological tissue and in tumors, particularly in neuroendocrine tumors …

In recent years, targeted radionuclide therapy (TRT) has emerged as a promising strategy
for cancer treatment. In contrast to conventional radiotherapy, TRT delivers ionizing radiation …

With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear
medicine as valuable diagnostic or treatment option, radiobiology plays an important role in …

The treatment options that are currently available for management of metastatic, progressive
radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary …

Non-functioning pituitary adenomas, recently alternatively termed pituitary neuroendocrine
tumours (NFpitNETs), are mostly benign neoplasms that are not associated with a hormonal …

Clinical options for systemic therapy of neuroendocrine tumors (NET) are limited.
Development of new drugs requires suitable representative in vitro and in vivo model …